Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate 11:18:25 2024-07-08 am EDT 5-day change 1st Jan Change
9.897 EUR +10.09% Intraday chart for Grifols, S.A. +21.63% -36.05%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading MT
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion? Alphavalue
That's not so bad, is it? Our Logo
Top Premarket Gainers MT
TSX futures muted as commodities decline amid rate cut hopes RE
Trending : Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended MT
Grifols Faces Delisting Bid From Founding Family and Brookfield DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended MT
Grifols says founding family, Brookfield looking to delist drugmaker RE
Grifols Receives Takeover Interest from Founding Family, Brookfield MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care MT
Grifols Appoints New Chief Financial Officer MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading MT
Spain's Grifols Appoints New Finance Chief MT
Spanish drugmaker Grifols appoints new finance chief as shake-up continues RE
Grifols Stakeholder Scranton Enterprises Said in Talks for EUR130 Million Loan MT
Global markets live: Eli Lilly, Apple, Walmart, Shell, Rio Tinto... Our Logo
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
Grifols Stakeholder Scranton Enterprises Said in Talks for EUR130 Million Loan MT
Scranton, linked to Grifols family, reaches agreement to refinance debt RE
Unit of Grifols shareholder Scranton reaches debt refinancing deal RE
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June MT
Grifols' Biotest Set to Launch Intravenous Immunoglobulin in US in Q1 2025 MT
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
8.99 EUR
Average target price
17.41 EUR
Spread / Average Target
+93.62%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols: A strategic move or a ploy to arrest further shareholder wealth erosion?